Kisspeptin

Kisspeptin is a neuropeptide involved in regulation of GnRH signaling. Investigations in reproductive endocrinology examine its role in reproductive hormone control and fertility. These research interests do not establish an approved therapeutic use; FDA approval is absent.

• Hormonal Regulation

  Most effective

  Direct endocrine activity produces effects on hormone regulation that are well characterized.

• Reproductive Health

  Effective

  Fertility investigations and reproductive medicine are areas of research and clinical application.

• Metabolic Support

  Moderate

  Hormonal signaling may produce secondary effects on metabolic function.

• Medications

  Caution

  Consult your prescriber before combining this compound with any medication.

• BPC-157

  Compatible

• NAD+

  Compatible

• Vitamin D

  Compatible

Diluent: Use bacteriostatic water only; avoid saline because precipitation can occur.

1. Let the refrigerated vial warm to room temperature for 15–20 minutes before preparing it.
2. Disinfect the stopper using an alcohol swab, then wait until the surface has dried fully in the air.
3. Use a sterile syringe to measure your calculated amount of bacteriostatic water. Use this diluent only; avoid saline because precipitation may occur.
4. Introduce the water gradually against the inner glass wall. Keep the stream away from the peptide powder itself.
5. Rotate the vial gently to mix its contents. Do not shake forcefully, because vigorous agitation can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
7. Measure your calculated dose with an insulin syringe in preparation for administration beneath the skin.
8. Use the abdomen, thigh or upper arm for subcutaneous administration. Change the injection location each time to help prevent lipodystrophy.
9. Return the mixed vial to refrigeration at 2–8°C. Use the prepared solution within 28 days of mixing.

Week 1–2

Early effects may accompany an adjustment period. Watch for any unwanted reaction as you adapt.

Week 2–4

The principal effects may begin emerging. Follow your clinician’s recommendations for any change in dose.

Week 4–8

Main effects are expected to be apparent at this stage. Review your progress together with your clinician.

Week 8+

Review the outcome with your clinician and decide whether to continue, take a cycle break or adjust the dose. These timings do not establish effectiveness for every compound.

• Bruising, redness or mild soreness where the injection is given
• Possible allergic response; stop use if you develop hives or a rash
• Variable individual response; begin with the lowest dose and watch closely for reactions
• Discuss use with your clinician beforehand and report symptoms that are unusual for you

Kisspeptin: not approved in the US.

• US

  Not approved

  FDA — experimental use only, without therapeutic approval. The regulatory record indicates no prescription requirement, no 503A ban and no applicable telehealth pathway.

  Rx required

  No

  Telehealth

  N/A

1. Kisspeptin signaling in reproductive biology (2012)

2. Kisspeptin in the control of reproduction (2018)

3. Pubertal development and regulation. (2016)

   PMID 26852256DOI 10.1016/S2213-8587(15)00418-0

4. Kisspeptin and fertility. (2011)

   PMID 21084385DOI 10.1677/JOE-10-0265

5. Kisspeptin studies on ClinicalTrials.gov (2024)